Evidence map›Paper›PMID 37416479›Full record

ArticleiScience2023

The potential therapeutic regimen for overcoming resistance to osimertinib due to rare mutations in NSCLC.

Rui Han, Caiyu Lin, Chong Zhang, Jun Kang, Conghua Lu, Yiming Zhang, Yubo Wang, Chen Hu, Yong He

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Rui HanDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.
Caiyu LinDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.
Chong ZhangDepartment of Ultrasound, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Jun KangDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.
Conghua LuDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.
Yiming ZhangDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.
Yubo WangDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.
Chen HuDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.
Yong HeDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.
Army Medical University · CNThe Affiliated Yongchuan Hospital of Chongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mechanisms of osimertinib resistance have not been well characterized. We conducted next-generation sequencing to recognize novel resistance mechanism and used cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models to evaluate the anti-proliferative effects of aspirin

Indexed as

CancerMolecular geneticsMolecular interaction

Identifiers

PMID37416479
PMCPMC10320197
OpenAlexW4380356708

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.